For patients with symptomatic sickness necessitating therapy, ibrutinib is often proposed according to 4 section III randomized scientific trials comparing ibrutinib with chlorambucil monotherapy106 and also other frequently employed CIT combinations, namely FCR, bendamustine additionally rituximab and chlorambucil plus obinutuzumab (ClbO).107–10